Resumos
La amiodarona (AMD) es una droga antiarritmica cuyos efectos adversos pueden comprometer el sistema nervioso central y periferico. La aparición de un síndrome cerebeloso es infrecuente. Se presenta un paciente masculino de 56 anos de edad que desarolla un síndrome pancerebeloso de 4 meses de evolución, que revierte luego de la suspension de la AMD. El cuadro reaparece meses mas tarde luego de un periodo de automedicacion con la droga. Los mecanismos tóxicos por los cuales la AMD afecta al cerebelo permanecen inciertos. Esta droga de amplia difusión en nuestro medio, como otros antiarritmicos, posee efectos sobre el sistema nervioso que deben ser tenidos en cuenta a fin de poder detectarlos precozmente.
síndrome cerebeloso; amiodarona
Amidarone (AMD) is an antiarrhytmic drug with side effects on the nervous system. Cerebellum is seldom involved. We describe the case of a 56 years old male patient with a history of 4 month of cerebellar involvement characterized by gait unstadiness, ataxia, nistagmus and vertigo. He was on treatment with AMD because of ventricular arrythmia. The cerebellar syndrom progressively disappeared after drug whitdrawal and he was symptoms-free 4 months later. Similar symptoms appeared after another one month of automedication with the same drug. Structural lesions, metabolic, nutritional deficiencies or toxics were excluded. Mechanisms of cerebellar toxicity of AMD are yet unknown. The knowledge of the toxic effects of this drug, widely used in our country, would allow its early recognition.
cerebellar syndrome; amiodarone
síndrome cerebeloso; amiodarona
cerebellar syndrome; amiodarone
Síndrome cerebeloso por amiodarona
Cerebellar syndrome by amiodarone
Neuda S. Garretto; Roberto D. Rey; Guillermo Kohler; Silvia Cocorullo; David A. Monteverde; Blanca I. Ravera; Roberto E.P. Sica
Division Neurologia, Hospital Jose Maria Ramos Mejia, Buenos Aires. Argentina
RESUMEN
La amiodarona (AMD) es una droga antiarritmica cuyos efectos adversos pueden comprometer el sistema nervioso central y periferico. La aparición de un síndrome cerebeloso es infrecuente. Se presenta un paciente masculino de 56 anos de edad que desarolla un síndrome pancerebeloso de 4 meses de evolución, que revierte luego de la suspension de la AMD. El cuadro reaparece meses mas tarde luego de un periodo de automedicacion con la droga. Los mecanismos tóxicos por los cuales la AMD afecta al cerebelo permanecen inciertos. Esta droga de amplia difusión en nuestro medio, como otros antiarritmicos, posee efectos sobre el sistema nervioso que deben ser tenidos en cuenta a fin de poder detectarlos precozmente.
Palabras-llave: síndrome cerebeloso, amiodarona.
SUMMARY
Amidarone (AMD) is an antiarrhytmic drug with side effects on the nervous system. Cerebellum is seldom involved. We describe the case of a 56 years old male patient with a history of 4 month of cerebellar involvement characterized by gait unstadiness, ataxia, nistagmus and vertigo. He was on treatment with AMD because of ventricular arrythmia. The cerebellar syndrom progressively disappeared after drug whitdrawal and he was symptoms-free 4 months later. Similar symptoms appeared after another one month of automedication with the same drug. Structural lesions, metabolic, nutritional deficiencies or toxics were excluded. Mechanisms of cerebellar toxicity of AMD are yet unknown. The knowledge of the toxic effects of this drug, widely used in our country, would allow its early recognition.
Key words: cerebellar syndrome, amiodarone.
Texto completo disponível apenas em PDF.
Full text available only in PDF format.
Aceite: 11-junho-1994.
Dra. Nelida S. Garretto - Division Neurologia Hospital Ramos Mejia - Urquiza 609 - 1221 - Buenos Aires -Argentina.
- 1. Charness ME, Morady F, Scheinman M. Frequent neurologic toxicity associated with amiodarone therapy. Neurology 1984, 34: 669-671.
- 2. Costa-Jussa FR, Jacobs JM. The pathology of amiodarone neurotoxicity: I. Experimental studies with reference to changes in other tissues. Brain 1985, 108: 735-752.
- 3. Dudognon P, Hauw JJ, De Baecque C. Neuropathie au chlorhydrate d'amiodarone. Rev Neurol (Paris) 1979, 135: 527-540.
- 4. Fogoros RN, Anderson KP, Winkle RA, Swerdlow CD, Mason JW. Amiodarone: clinical efficacy and toxicity in 96 patients with recurrent, drug-refractory arrhythmias. Circulation 1983, 68: 88-94.
- 5. Jacobs JM, Costa-Jussa FR. The pathology of amiodarone neurotoxicity: II. Peripheral neuropathy in man. Brain 1985, 108: 753-769.
- 6. Martinez Arizala A, Sobol SM, Mc Carty GE, Nichols BR, Rakita L. Amiodarone neuropathy. Neurology 1983, 33: 643-645.
- 7. Micheli F, Romano E, Dominguez R, Gatto E. Parkinsonism secondary to amiodarone therapy. Rev Neurol Argent 1992, 17: 56-58.
- 8. Mizon JP, Rosa A, Betermiez P, Sevestre H. Neuropathie et syndrome cerebelleux a 1' amiodarone. Rev Neurol (Paris) 1985, 141: 146-148.
- 9. Pellissier JF, Pouget J, Cros D, Serratrice V, Toga M. Peripheral neuropathy induced by amiodarone chlorhydrate: a clinicopathological study. J Neurol Sci 1984, 63: 251-266.
- 10. Podrid PJ, Lown B. Amiodarone therapy in symptomatic, sustained refractory atrial and ventricular tachyarrhythmias. Am Heart J 1981, 101: 374-379.
- 11. Werner EG, Olanou CW. Parkinsonism and amiodarone therapy. Ann Neurol 1989, 25: 630-632.
Datas de Publicação
-
Publicação nesta coleção
19 Jan 2011 -
Data do Fascículo
Dez 1994
